Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.

Takenaka T, Nakai S, Katayama M, Hirano M, Ueno N, Noguchi K, Takatani-Nakase T, Fujii I, Kobayashi SS, Nakase I.

Int J Pharm. 2019 Oct 11:118762. doi: 10.1016/j.ijpharm.2019.118762. [Epub ahead of print]

PMID:
31610280
2.

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.

Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS.

Mol Cancer Res. 2019 Aug 29. doi: 10.1158/1541-7786.MCR-19-0419. [Epub ahead of print]

PMID:
31467113
3.

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.

Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB.

J Thorac Oncol. 2019 Aug 1. pii: S1556-0864(19)30599-4. doi: 10.1016/j.jtho.2019.07.016. [Epub ahead of print]

PMID:
31377341
4.

Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.

Radhakrishnan S, Syed R, Takei H, Kobayashi IS, Nakamura E, Sultana F, Kamal A, Tenen DG, Kobayashi SS.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2286-2289. doi: 10.1016/j.bmcl.2019.06.024. Epub 2019 Jun 20.

PMID:
31278031
5.

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.

Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):10025-10030. doi: 10.1073/pnas.1819430116. Epub 2019 May 1.

6.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB.

Clin Cancer Res. 2018 Dec 15;24(24):6548-6555. doi: 10.1158/1078-0432.CCR-18-1541. Epub 2018 Aug 28.

PMID:
30154228
7.

Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα.

Sridhar R, Takei H, Syed R, Kobayashi IS, Hui LB, Kamal A, Tenen DG, Kobayashi SS.

Molecules. 2018 Aug 3;23(8). pii: E1938. doi: 10.3390/molecules23081938.

8.

[Transcription factor-based therapies for acute myeloid leukemia].

Kobayashi SS, Takei H.

Rinsho Ketsueki. 2018;59(7):922-931. doi: 10.11406/rinketsu.59.922. Review. Japanese.

PMID:
30078804
9.

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.

Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB.

J Thorac Oncol. 2019 Jan;14(1):e1-e3. doi: 10.1016/j.jtho.2018.06.020. Epub 2018 Jul 5. No abstract available.

PMID:
29981924
10.

Targeting transcription factors in acute myeloid leukemia.

Takei H, Kobayashi SS.

Int J Hematol. 2019 Jan;109(1):28-34. doi: 10.1007/s12185-018-2488-1. Epub 2018 Jun 28. Review.

PMID:
29956082
11.

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2018 Feb;116:90-95. doi: 10.1016/j.lungcan.2018.01.002. Epub 2018 Jan 4.

12.

ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα.

Gonzalez D, Luyten A, Bartholdy B, Zhou Q, Kardosova M, Ebralidze A, Swanson KD, Radomska HS, Zhang P, Kobayashi SS, Welner RS, Levantini E, Steidl U, Chong G, Collombet S, Choi MH, Friedman AD, Scott LM, Alberich-Jorda M, Tenen DG.

J Biol Chem. 2017 Nov 17;292(46):18924-18936. doi: 10.1074/jbc.M117.811109. Epub 2017 Sep 12.

13.

Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.

Takenaka T, Katayama M, Sugiyama A, Hagiwara M, Fujii I, Takatani-Nakase T, Kobayashi SS, Nakase I.

Anticancer Res. 2017 Sep;37(9):4779-4788.

PMID:
28870896
14.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 Nov;12(11):e175-e177. doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10. No abstract available.

15.

Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis.

Jin J, Zhan P, Katoh M, Kobayashi SS, Phan K, Qian H, Li H, Wang X, Wang X, Song Y; written on behalf of the AME Lung Cancer Collaborative Group.

Transl Lung Cancer Res. 2017 Feb;6(1):97-108. doi: 10.21037/tlcr.2017.02.07.

16.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB.

Lung Cancer. 2017 Apr;106:17-21. doi: 10.1016/j.lungcan.2017.01.011. Epub 2017 Jan 25.

17.

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.

Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16.

18.

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2016 Sep;99:17-22. doi: 10.1016/j.lungcan.2016.06.006. Epub 2016 Jun 14.

19.

Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.

Kobayashi SS, Vali S, Kumar A, Singh N, Abbasi T, Sayeski PP.

Oncotarget. 2016 Jun 14;7(24):35989-36001. doi: 10.18632/oncotarget.8540.

20.

Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

Costa DB, Jorge SE, Moran JP, Freed JA, Zerillo JA, Huberman MS, Kobayashi SS.

J Thorac Oncol. 2016 Jun;11(6):918-23. doi: 10.1016/j.jtho.2016.02.016. Epub 2016 Mar 8.

21.

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.

Costa DB, Kobayashi SS.

Transl Lung Cancer Res. 2015 Dec;4(6):809-15. doi: 10.3978/j.issn.2218-6751.2015.05.05.

22.

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB.

Lung Cancer. 2015 Dec;90(3):369-74. doi: 10.1016/j.lungcan.2015.10.028. Epub 2015 Oct 31.

23.

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K.

Oncotarget. 2015 Nov 17;6(36):38789-803. doi: 10.18632/oncotarget.5887.

24.

A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation.

Radomska HS, Jernigan F, Nakayama S, Jorge SE, Sun L, Tenen DG, Kobayashi SS.

J Biomol Screen. 2015 Oct;20(9):1150-9. doi: 10.1177/1087057115592220. Epub 2015 Jun 24.

25.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB.

Clin Lung Cancer. 2015 Sep;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. Epub 2015 Mar 25. No abstract available.

26.

CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma.

Cai Y, Hirata A, Nakayama S, VanderLaan PA, Levantini E, Yamamoto M, Hirai H, Wong KK, Costa DB, Watanabe H, Kobayashi SS.

PLoS One. 2015 Mar 13;10(3):e0120647. doi: 10.1371/journal.pone.0120647. eCollection 2015.

27.

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.

Jorge SE, Kobayashi SS, Costa DB.

Braz J Med Biol Res. 2014 Nov;47(11):929-39. Epub 2014 Sep 5. Review.

28.

β-catenin contributes to lung tumor development induced by EGFR mutations.

Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, Tan AJ, Yamaguchi N, Yasuda H, Li D, Soejima K, Soo RA, Costa DB, Wong KK, Kobayashi SS.

Cancer Res. 2014 Oct 15;74(20):5891-902. doi: 10.1158/0008-5472.CAN-14-0184. Epub 2014 Aug 27.

29.

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.

J Thorac Oncol. 2014 Feb;9(2):248-53. doi: 10.1097/JTO.0000000000000050.

30.

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.

Sci Transl Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205. Erratum in: Sci Transl Med. 2014 Feb 26;6(225):225er1.

31.

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR.

J Clin Virol. 2009 Dec;46(4):305-8. doi: 10.1016/j.jcv.2009.09.025. Epub 2009 Oct 12.

Supplemental Content

Loading ...
Support Center